The CHRONICLE Study: A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individuals With Severe Asthma in the United States
Latest Information Update: 19 Mar 2025
At a glance
- Drugs Benralizumab (Primary) ; Dupilumab (Primary) ; Mepolizumab (Primary) ; Omalizumab (Primary) ; Reslizumab (Primary)
- Indications Asthma
- Focus Adverse reactions; Therapeutic Use
- Acronyms CHRONICLE
- Sponsors AstraZeneca
Most Recent Events
- 14 Mar 2025 Status changed from active, no longer recruiting to completed.
- 25 Nov 2024 Status changed from recruiting to active, no longer recruiting.
- 22 May 2024 Results (Between February 2018 and July 2022, among 754 patients with SA not receiving biologics, 180 identified as Black and 574 as non-Black and not Hispanic/Latino ethnicity) assessing to identify factors associated with race that might explain the observed increased exacerbation risk, presented at the 120th International Conference of the American Thoracic Society.